An interventional study of Romiplostim N01 and Rituximab in Primacy Immune Thrombocytopenia, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Treatment
The primary objective of this trial is to assess the efficacy and safety of combining Romiplostim N01 with Rituximab for the treatment of adult patients with primary immune thrombocytopenia (ITP) whose disease is refractory to oral TPO-RAs.
All participants in this study will receive the same combination treatment:
Rituximab: Given once a week through an intravenous infusion for 4 weeks. Romiplostim N01: Given as a weekly injection，the dose may be adjusted each week based on the patient's platelet count.
Participants will be asked to:
Visit the clinic regularly for check-ups, blood tests (to monitor platelet counts), and safety assessments.
Report their bleeding symptoms for evaluation. This is an open-label, single-arm trial, meaning that all participants will receive the investigational treatment, and both the research team and participants will be aware of the treatment assigned. The study aims to enroll approximately 30 adult patients aged 14 years or older who have been diagnosed with ITP and have not responded adequately to prior oral TPO-RAs (eltrombopag/hetrombopag).
The First Affiliated Hospital of Soochow University is the lead sponsor of 252 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Confirmed diagnosis of primary immune thrombocytopenia (ITP).
Age ≥14 years.
Prior exposure to at least one ITP-directed therapy (e.g., corticosteroids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO-RAs, immunosuppressants, or splenectomy), including a minimum 4-week course of an oral TPO-RA (hetrombopag or eltrombopag) that was discontinued due to insufficient response.
Platelet count \< 30 × 10⁹/L at screening, OR platelet count \< 50 × 10⁹/L with concurrent clinically significant bleeding.
Stable glucocorticoid dose (e.g., prednisone or methylprednisolone, not exceeding 4 tablets daily) for at least 2 weeks, and stable dosing of any other immunosuppressants for at least 4 weeks prior to enrollment.
No receipt of intravenous immunoglobulin within 2 weeks before the first dose of study treatment.
No platelet transfusion within 1 week before the first dose of study treatment.
Exclusion Criteria:
Secondary ITP due to underlying conditions such as other autoimmune disorders, viral infections, or drug exposure.
Presence of active malignancy, pregnancy, significant cardiovascular or cerebrovascular disease, or history of arterial/venous thrombosis.
Drug: Romiplostim N01 · Drug: Rituximab
Romiplostim N01 will be administered via subcutaneous injection once weekly based on the platele count. The starting dose is set at 3 μg/kg. Weekly dose adjustments will be guided by platelet counts measured immediately prior to administration, as follows: For a platelet count below 50 × 10⁹/L, the dose will be increased by 1 μg/kg. For a platelet count between 50 and 200 × 10⁹/L, the current dose will be maintained as the minimum therapeutic dose for bleeding risk reduction. For a platelet count between 200 and 400 × 10⁹/L, the dose will be decreased by 1 μg/kg. For a platelet count exceeding 400 × 10⁹/L, the administration will be withheld. It is stipulated that dosing will resume at a reduction of 1 μg/kg from the previous dose once the platelet count returns to 200 × 10⁹/L or below. Under no circumstances shall the dose exceed the maximum allowable limit of 10 μg/kg per week.
Rituximab will be administered in accordance with the Chinese guidelines for the diagnosis and management of adult primary immune thrombocytopenia (2020 edition). The dosage will be 375 mg/m² per infusion, administered via intravenous infusion once weekly for a total of four weeks.
Efficacy evaluation
Efficacy assessments (platelet count) are performed weekly from Week 2 to Week 8, and then monthly until Month 12. Efficacy evaluation relies on time to platelet response, overall response rate, complete response rate and maintained response rate
Time frame: from week 2 to month 12
Incidence of severe Adverse Events
Adverse events include the monitoring of the incidence of thrombotic events, myelofibrosis, and severe infections.
Time frame: up to 12 months
Long-term Sustained Response Rate versus Relapse Rate
Time frame: at 6 months and 12 months
Proportion of Participants Achieving a Rapid Platelet Response
Platelet count is assessed weekly during this period
Time frame: within the first 8 weeks of treatment
Change in Bleeding Score Over Time
Time frame: up to 12 months
Incidence of other adverse events
Recording the incidence of other adverse events, such as liver and kidney dysfunction, and hypersensitivity reactions.
Time frame: up to 12 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Soochow University